Volume 21 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(4): 602-605
ZHU Zhangjin, LI Jingfeng, WANG Chao, LI Yin, NIU Jie, XU Xiaofei, HU Hao. Effect of sacubitril/valsartan on left atrial remodeling in patients with class Ⅳ cardiac function[J]. Chinese Journal of General Practice, 2023, 21(4): 602-605. doi: 10.16766/j.cnki.issn.1674-4152.002940
Citation: ZHU Zhangjin, LI Jingfeng, WANG Chao, LI Yin, NIU Jie, XU Xiaofei, HU Hao. Effect of sacubitril/valsartan on left atrial remodeling in patients with class Ⅳ cardiac function[J]. Chinese Journal of General Practice, 2023, 21(4): 602-605. doi: 10.16766/j.cnki.issn.1674-4152.002940
shu

Effect of sacubitril/valsartan on left atrial remodeling in patients with class Ⅳ cardiac function

doi: 10.16766/j.cnki.issn.1674-4152.002940
  • 1.

    Department of Cardiology, the First People's Hospital of Chuzhou, Chuzhou, Anhui 239000, China

Funds:

 AHWJ2021b080

  • Received Date: 2022-07-04
    Available Online: 2023-05-31
    Abstract
  •   Objective  To investigate the effects of sacubitril/valsartan on the left atrial parameters and remodeling in echocardiography among patients with New York Heart Association(NYHA) class Ⅳ heart failure.  Methods  A total of 90 heart failure and a reduced ejection fraction (HFrEF) patients with NYHA class Ⅳ hospitalized in the First People's Hospital of Chuzhou were retrospectively analyzed. According to drug treatment, they were divided into two groups: the angiotensin enkephalin inhibitor (ARNI) group (48 cases) and the angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor antagonist (ACEI/ARB) group (42 cases), and the changes and amplitude of left atrial remodeling ultrasound indexes in the two groups after 1 year of treatment were compared.  Results  During follow up, the left atrial transverse diameter (LATD) in ARNI group was significantly shorter than that in ACEI/ARB group [(-6.92±4.09) mm vs. (-3.60±4.48) mm, P < 0.001]; the left atrial volume (LAV) of ARNI group was significantly smaller than that of ACEI/ARB group [(-11.76±5.73) mL vs. (-8.14±6.21) mL, P=0.005]; the left atrial volume index (LAVI) in ARNI group decreased more significantly than that in ACEI/ARB group [(-6.38±4.55) mL/m2 vs. (-4.16±3.69) mL/m2, P=0.014)]; the left atrial globular index (LASI) in ARNI group decreased more significantly than that in ACEI/ARB group (-0.09±0.14 vs. 0.01±0.11, P=0.003). In addition, the number of patients with left atrial reverse remodeling (LARR) in ARNI group was higher [26 (54.2%) vs. 14 (33.3%), P=0.047].  Conclusion  Compared with ACEI/ARB group, the treatment of sacubitril/valsartan can better reduce the LATD, LAV, LAVI, LASI, and improve LARR in HFrEF patients with NYHA class Ⅳ.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    DOCHERTY K F, VADUGANATHAN M, SOLOMON S D, et al. Sacubitril/Valsartan: neprilysin inhibition 5 years after PARADIGM-HF[J]. JACC Heart Fail, 2020, 8(10): 800-810. doi: 10.1016/j.jchf.2020.06.020
    [2]
    SUN Y, SONG S, ZHANG Y, et al. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure[J]. ESC Heart Fail, 2022, 9(1): 667-675. doi: 10.1002/ehf2.13691
    [3]
    MANN D L, GIVERTZ M M, VADER J M, et al. Effect of treatment with Sacubitril /Valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA Cardiol, 2022, 7(1): 17-25. doi: 10.1001/jamacardio.2021.4567
    [4]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南(2018)[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004

    Heart Failure Group, Chinese Society of Cardiology, Chinese Medical Doctor Association, Heart Failure Committee, Editorial Committee of Chinese Journal of Cardiology. Chinese guideline for diagnosis and treatment of heart failure 2018[J]. Chinese Journal of Cardiology, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [5]
    CASTRICHINI M, MANCA P, NUZZI V, et al. Sacubitril/Valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: standard and advanced echocardiographic evidences[J]. J Clin Med, 2020, 9(4): 906. doi: 10.3390/jcm9040906
    [6]
    黎冉, 谢丽娟, 焦长青, 等. 沙库巴曲缬沙坦对不同射血分数心力衰竭患者的疗效及预后[J]. 中华全科医学, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716

    LI R, XIE L J, JIAO C Q, et al. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with dif-ferent ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(1): 10-13. doi: 10.16766/j.cnki.issn.1674-4152.001716
    [7]
    MELO M, CAIFFA T, GOBBO M, et al. Reverse remodeling in dilated cardiomyo-pathy: insights and future perspectives[J]. Int J Cardiol Heart Vasc, 2018, 18: 52-57. http://www.sciencedirect.com/science/article/pii/S2352906718300071/pdfft?md5=733e22ca27aec5e42b479764ac28bad3&pid=1-s2.0-S2352906718300071-main.pdf
    [8]
    THOMAS L, MARWICK T H, POPESCU B A, et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2019, 73(15): 1961-1977. doi: 10.1016/j.jacc.2019.01.059
    [9]
    OKUTUCU S, FATIHOGLU S G, SABANOGLU C, et al. Effect of angiotensin rece-ptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction[J]. Herz, 2021, 46(Suppl1): 69-74.
    [10]
    BOUWMEESTER S, MAST T P, KEULARDS D C J, et al. Left atrial reverse remodeling predicts long-term survival after cardiac resynchronization therapy[J]. J Echocardiogr, 2022, 20(2): 115-123. doi: 10.1007/s12574-021-00559-0
    [11]
    GÜZEL T, KIŞ M, ŞENÖZ O. The correlation between the left atrial volume index and atrial fibrillation development in heart failure with mildly reduced ejection fraction and long-term follow-up results[J]. Acta Cardiol, 2022, 4(24): 1-8.
    [12]
    RI T, SAITO C, ARASHI H, et al. Increased left atrial volume index is associated with more cardiovascular events in patients with acute coronary syndrome: HIJ-PROPER study findings[J]. Echocardiography, 2022, 39(2): 260-267. doi: 10.1111/echo.15301
    [13]
    KHAN M S, FELKER G M, PIÑA I L, et al. Reverse cardiac remodeling following initiation of Sacubitril/Valsartan in patients with heart failure with and without diabetes[J]. JACC Heart Fail, 2021, 9(2): 137-145. doi: 10.1016/j.jchf.2020.09.014
    [14]
    YAZAKI M, NABETA T, INOMATA T, et al. Clinical significance of left atrial geometry in dilated cardiomyopathy patients: a cardiovascular magnetic resonance study[J]. Clin Cardiol, 2021, 44(2): 222-229. doi: 10.1002/clc.23529
    [15]
    NAKAMORI S, NGO L H, TUGAL D, et al. Incremental value of left atrial geometric remodeling in predicting late atrial fibrillation rcurr- ence after pulmonary vein isolation: a cardiovascular magnetic reson- ance study[J]. J Am Heart As-soc, 2018, 19: 1-13. http://www.ncbi.nlm.nih.gov/pubmed/30371333
    [16]
    LI L Y, LOU Q, LIU G Z, et al. Sacubitril/Valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J]. Eur J Pharmacol, 2020, 881: 173120. DOI: 10.1016/j.ejphar.2020.173120.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (235) PDF downloads(14) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return